IMM-101

IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).